 | |
| Clinical data | |
|---|---|
| Other names | RU24213; 3-Hydroxy-N-propyl-N-(phenylethyl)phenethylamine |
| Drug class | Dopamine receptor agonist;DopamineD2-like receptoragonist;κ-Opioid receptor antagonist |
| ATC code |
|
| Identifiers | |
| |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H25NO |
| Molar mass | 283.415 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RU-24213, also known as3-hydroxy-N-propyl-N-(phenylethyl)phenethylamine, is adopamine receptor agonist of thephenethylamine family related todopamine.[1][2][3] It is aselectivedopamineD2-like receptoragonist.[1][3] Subsequently, however, RU-24213 was found to also act as apotentκ-opioid receptor (KOR)antagonist.[2][4] It led to the development of the diphenylethylamine series of KORligands.[4][5] RU-24213 was first described in thescientific literature in 1978.[4][6]
The synthesis of the first diphenethylamine derivative, RU 24213 (1) (Fig. 10), was reported in 1978, originally developed as a potential anti-Parkinson's drug (Nedelec et al. 1978). RU 24213 (1) was described as a selective dopamine D2 receptor agonist (Euvrard et al. 1980), also found to bind with moderate affinity and selectivity to KOR and to have a KOR antagonist activity in vitro (Fortin et al. 1991). [...] These simple structures were used as leads for the design of small molecules targeting the KOR and featuring a diphenethylamine scaffold. [...]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |